Opdenakker G - Search Results

1

Microglia emerge from erythromyeloid precursors via Pu.1- and Irf8-dependent pathways.

Kierdorf K, Erny D, Goldmann T, Sander V, Schulz C, Perdiguero EG, Wieghofer P, Heinrich A, Riemke P, Hölscher C, Müller DN, Luckow B, Brocker T, Debowski K, Fritz G, Opdenakker G, Diefenbach A, Biber K, Heikenwalder M, Geissmann F, Rosenbauer F, Prinz M. Kierdorf K, et al. Among authors: opdenakker g. Nat Neurosci. 2013 Mar;16(3):273-80. doi: 10.1038/nn.3318. Epub 2013 Jan 20. Nat Neurosci. 2013. PMID: 23334579

2

Distinct expression patterns and levels of enzymatic activity of matrix metalloproteinases and their inhibitors in primary brain tumors.

Pagenstecher A, Wussler EM, Opdenakker G, Volk B, Campbell IL. Pagenstecher A, et al. Among authors: opdenakker g. J Neuropathol Exp Neurol. 2001 Jun;60(6):598-612. doi: 10.1093/jnen/60.6.598. J Neuropathol Exp Neurol. 2001. PMID: 11398836

3

Zymography methods for visualizing hydrolytic enzymes.

Vandooren J, Geurts N, Martens E, Van den Steen PE, Opdenakker G. Vandooren J, et al. Among authors: opdenakker g. Nat Methods. 2013 Mar;10(3):211-20. doi: 10.1038/nmeth.2371. Nat Methods. 2013. PMID: 23443633 Review.

4

Metalloproteinases and specific inhibitors in multiple sclerosis: from blood to brain or vice versa?

Opdenakker G. Opdenakker G. Brain. 1999 Feb;122 ( Pt 2):181-2. doi: 10.1093/brain/122.2.181. Brain. 1999. PMID: 10071046 No abstract available.

5

Blood-brain barrier resealing in neuromyelitis optica occurs independently of astrocyte regeneration.

Winkler A, Wrzos C, Haberl M, Weil MT, Gao M, Möbius W, Odoardi F, Thal DR, Chang M, Opdenakker G, Bennett JL, Nessler S, Stadelmann C. Winkler A, et al. Among authors: opdenakker g. J Clin Invest. 2021 Mar 1;131(5):e141694. doi: 10.1172/JCI141694. J Clin Invest. 2021. PMID: 33645550 Free PMC article.

6

Matrix metalloproteinase expression in an experimentally-induced DTH model of multiple sclerosis in the rat CNS.

Anthony DC, Miller KM, Fearn S, Townsend MJ, Opdenakker G, Wells GM, Clements JM, Chandler S, Gearing AJ, Perry VH. Anthony DC, et al. Among authors: opdenakker g. J Neuroimmunol. 1998 Jul 1;87(1-2):62-72. doi: 10.1016/s0165-5728(98)00046-0. J Neuroimmunol. 1998. PMID: 9670846

7

"Reverse degradomics", monitoring of proteolytic trimming by multi-CE and confocal detection of fluorescent substrates and reaction products.

Piccard H, Hu J, Fiten P, Proost P, Martens E, Van den Steen PE, Van Damme J, Opdenakker G. Piccard H, et al. Among authors: opdenakker g. Electrophoresis. 2009 Jul;30(13):2366-77. doi: 10.1002/elps.200800698. Electrophoresis. 2009. PMID: 19621364

8

Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy.

Nelissen I, Martens E, Van den Steen PE, Proost P, Ronsse I, Opdenakker G. Nelissen I, et al. Among authors: opdenakker g. Brain. 2003 Jun;126(Pt 6):1371-81. doi: 10.1093/brain/awg129. Brain. 2003. PMID: 12764058

9

Gelatinase B/matrix metalloproteinase-9 provokes cataract by cleaving lens betaB1 crystallin.

Descamps FJ, Martens E, Proost P, Starckx S, Van den Steen PE, Van Damme J, Opdenakker G. Descamps FJ, et al. Among authors: opdenakker g. FASEB J. 2005 Jan;19(1):29-35. doi: 10.1096/fj.04-1837com. FASEB J. 2005. PMID: 15629892

10

Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.

Hu J, Van den Steen PE, Sang QX, Opdenakker G. Hu J, et al. Among authors: opdenakker g. Nat Rev Drug Discov. 2007 Jun;6(6):480-98. doi: 10.1038/nrd2308. Nat Rev Drug Discov. 2007. PMID: 17541420 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

491 results

Search Page